Dement Neurocogn Disord.
2020 Jun;19(2):39-53. 10.12779/dnd.2020.19.2.39.
Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association
- Park KH
1 - Lim JS2
- Seo SW3
- Jeong Y4
- Noh Y1
- Koh eH5
- Bae Js6
- Park SA7
- Yang SJ8
- Kim HJ3
- Chin J3
- Roh Jh9
- An SSA10
- Korean Dementia Association
- Affiliations
-
- 1Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- 2Department of Neurology, Hallym University Sacred Heart Hospital, Hallym Neurological Institute, Hallym University College of Medicine, Anyang, Korea
- 3Department of Neurology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea
- 4Department of Bio and Brain Engineering, KAIST, Daejeon, Korea
- 5Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea
- 6Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea
- 7Lab for Neurodegenerative Dementia, Department of Anatomy and Department of Neurology, Ajou University School of Medicine, Suwon, Korea
- 8Department of Neurology, Yonsei University Health System, Seoul, Korea
- 9Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
- 10Department of Bionano Technology, Gachon University, Seongnam, Korea
- KMID: 2503503
- DOI: http://doi.org/10.12779/dnd.2020.19.2.39
Abstract
- Because of repeated failures of clinical trials, the concept of Alzheimer's disease (AD) has been changing rapidly in recent years. As suggested by the National Institute on Aging and the Alzheimer's Association Research Framework, the diagnosis and classification of AD is now based on biomarkers rather than on symptoms, allowing more accurate identification of proper candidates for clinical trials by pathogenesis and disease stage. Recent development in neuroimaging has provided a way to reveal the complex dynamics of amyloid and tau in the brain in vivo, and studies of blood biomarkers are taking another leap forward in diagnosis and treatment of AD. In the field of basic and translational research, the development of animal models and a deeper understanding of the role of neuroinflammation are taking a step closer to clarifying the pathogenesis of AD. Development of big data and the Internet of Things is also incorporating dementia care and research into other aspects. Largescale genetic research has identified genetic abnormalities that can provide a foundation for precision medicine along with the aforementioned digital technologies. Through the first international conference of the Korean Dementia Association, experts from all over the world gathered to exchange opinions with association members on these topics. The Academic Committee of the Korean Dementia Association briefly summarizes the contents of the lectures to convey the depth of the conference and discussions. This will be an important milestone in understanding the latest trends in AD's pathogenesis, diagnostic and therapeutic research and in establishing a future direction.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association
- Relationship Between Sleep and Alzheimer’s Dementia
- Prevention and Treatment of Vascular Dementia
- Executive Summary of 2023 International Conference of the Korean Dementia Association (IC-KDA 2023): A Report From the Academic Committee of the Korean Dementia Association
- Treatment of Vascular Dementia: A Comprehensive Review
